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Abstract
Background: Treatments for inflammatory bowel disease (IBD) are modestly effective and associated with side effects from
prolonged use. As there is no known cure for IBD, alternative therapeutic options are needed. Peroxisome proliferator-
activated receptor-gamma (PPARc) has been identified as a potential target for novel therapeutics against IBD. For this
project, compounds were screened to identify naturally occurring PPARc agonists as a means to identify novel anti-
inflammatory therapeutics for experimental assessment of efficacy.
Methodology/Principal Findings: Here we provide complementary computational and experimental methods to efficiently
screen for PPARc agonists and demonstrate amelioration of experimental IBD in mice, respectively. Computational docking
as part of virtual screening (VS) was used to test binding between a total of eighty-one compounds and PPARc. The test
compounds included known agonists, known inactive compounds, derivatives and stereoisomers of known agonists with
unknown activity, and conjugated trienes. The compound identified through VS as possessing the most favorable docked
pose was used as the test compound for experimental work. With our combined methods, we have identified a-eleostearic
acid (ESA) as a natural PPARc agonist. Results of ligand-binding assays complemented the screening prediction. In addition,
ESA decreased macrophage infiltration and significantly impeded the progression of IBD-related phenotypes through both
PPARc-dependent and –independent mechanisms in mice with experimental IBD.
Conclusions/Significance: This study serves as the first significant step toward a large-scale VS protocol for natural PPARc
agonist screening that includes a massively diverse ligand library and structures that represent multiple known target
pharmacophores.
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Introduction
Inflammatory bowel disease (IBD) is a chronic and recurring
inflammatory disease with two clinical manifestations: ulcerative
colitis (UC) and Crohn’s disease (CD). UC and CD affect over 4
million Americans and accrue a significant portion of the
estimated $1.7 billion in health care costs for prevalent
gastrointestinal diseases (CDC2007). While the etiopathogenesis
of IBD remains unclear, it has been suggested that chronic
mucosal inflammation characteristic of IBD is associated with a
disruption in immune homeostasis [1]. As such, treatments for
IBD should correct this immune dysregulation in order to prevent
or reduce gut mucosal damage.
There is no cure for IBD, but treatments are available to
combat the associated symptoms. One such treatment, 5-
aminosalicylic acid, targets the nuclear hormone receptor
peroxisome proliferator-activated receptor-gamma (PPARc),
which is highly expressed in the colonic epithelial and immune
cells [2–7]. PPARc and PPARd serve as targets for the treatment
of inflammatory and immune-mediated diseases because of the
role they play in maintaining homeostasis and suppressing
inflammation [1,7–9]. PPARc in particular is known to play a
role in transcriptional regulation of anti-inflammatory processes
via co-activator recruitment [6,9,10]. Ligand-induced activation of
PPARc can antagonize the activity of pro-inflammatory tran-
scription factors such as nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-kB), signal transducer and activator of
transcription (STAT), and activator protein (AP)-1 [11]. Other
IBD treatments currently available include infliximab, which is an
anti-tumor necrosis factor-alpha (TNF-a) antibody [12,13], and
corticosteroids, which systemically suppress immunity [14]. These
medications are modestly successful for the long-term manage-
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including increased risk of infection and cancer [15,16].
Interestingly, the insulin-sensitizing PPARc agonists used for
treating type 2 diabetes, such as rosiglitazone and pioglitazone,
have proven useful at ameliorating IBD effects in humans with UC
[17]. However, rosiglitazone, and other PPARc agonists of the
thiazolidinediones (TZD) class of anti-diabetic drugs, are unlikely
to be adopted by gastroenterologists for the treatment of IBD due
to associated side effects [17] including hepatotoxicity, weight
gain, fluid retention leading to edema, and congestive heart failure
[18]. In this regard, the U.S. Food and Drug Administration
(FDA) restricted the use of rosiglitazone in 2010 due to its side
effects, whereas the European Medicines Agency completely
banned its use in the European market. Natural therapeutics,
such as fatty acids that induce PPARc activation, might be a safer
alternative to current treatments and TZDs.
Our group has conducted several preclinical animal model
studies to suggest that supplementation of diet with fatty acids,
such as conjugated linoleic acid (CLA) [8,19] or agonistic
botanicals, is effective at ameliorating colonic inflammation in
mouse and pig models of IBD through a PPARc-dependent
mechanism [8,19–21]. In an effort to expedite the drug and
natural product therapeutic discovery process, virtual screening
(VS) can complement traditional experimental methods for
identification of novel PPARc agonists. VS represents a cost-
and time-efficient means of screening thousands of compounds
within thematic libraries that justify further experimental assess-
ment [22]. We are undertaking VS to identify novel PPARc
agonists within a collective of large compound databases. As a
feasibility test, we screened a small group of known and proposed
agonists, with the inclusion of known negative controls. The focus
of this small-scale screen was to test our PPARc structural model,
and assess binding of natural compounds, with significant
emphasis on conjugated trienes.
Conjugated trienes were selected due in part to their structural
similarity to CLA. In addition, conjugated trienes exhibit
effectiveness at ameliorating chronic inflammation [23,24]. One
such compound, a-eleostearic acid (ESA; 9Z11E13E-18:3), has
been found at concentrations of 60–80% in tung and bitter gourd
seed oils [25]. ESA has been shown to suppress tumor angiogenesis
[26] and MCF-7 breast cancer cell proliferation via PPARc
activation [27], induce apoptosis via lipid peroxidation [28], and
induce autophagy-dependent cell death through AKT/mTOR
and ERK1/2 signal targeting [29]. Evidence also indicates that
punicic acid plays a significant role in increasing lipid peroxidation
[30] and inhibiting TNF-a-induced neutrophil hyperactivation to
protect against experimentally induced colon inflammation in rats
[31]. Our group has found that punicic acid ameliorates type 2
diabetes-induced inflammation by activating PPARc and PPARa,
and repressing TNF-a expression in white adipose tissue and liver
[24] and increases peripheral insulin sensitivity [32] without
causing any adverse side effects [33]. We have also demonstrated
that punicic acid prevents experimental IBD through PPARc- and
PPARd-dependent mechanisms [34]. Catalpic acid improves
abdominal fat deposition, improves glucose homeostasis and up-
regulates PPARa expression in adipose tissue of mice [23].
Though these plant-derived conjugated trienes suggest anti-
inflammatory efficacy in various disease models, it has been
suggested that ESA induces a greater degree of antioxidant activity
than punicic acid in mice [35]. Punicic acid ameliorates both
diabetes [34] and gut inflammation [24] without causing side
effects [33], whereas ESA elicits mainly anti-inflammatory and
anti-carcinogenic effects [26–29]. A goal of this study was to test
the effectiveness of ESA in an experimental IBD model.
Additionally, small-scale VS was conducted to test the predict-
ability of our VS protocol for identifying PPARc full agonists in
the hopes of finding natural therapeutics and/or prophylactics for
treating IBD and other chronic inflammation-related diseases. The
computational portion of our study revealed information comple-
mentary to the predictions of our in vitro analysis, pre-clinical
efficacy, and mechanistic testing in mice.
Methods
Docking procedure
AutoDock 4.0 [36] (AD4) was used for structural model testing,
while AutoDock Vina [37] (Vina) was used for screening a subset
of our in-house ligand database against the selected structural
models of PPARc. AutoDock Tools 1.5.2 (ADT) was used to build
the appropriate charged protein and ligand files for docking.
Default values for the Lamarckian Genetic Algorithm (LGA) were
used for docking with AD4, with the exception of the maximum
number of energy evaluations, which was reduced to 250,000.
Adjusting this number reduced the screening time without
significantly affecting pose prediction. Five iterations of AD4 with
50 poses generated per iteration were conducted for the re-docking
step totaling 250 poses per protein structure model. Vina was used
for cross-docking and to run the small-scale screening. Three Vina
iterations were conducted for each ligand in the cross-docking
step, while a single run was conducted for the small-scale
screening. As a means to further sample conjugated triene
geometry, three AD4 iterations of 50 poses each were run for
each compound, which was a total of 150 poses per conjugated
triene for each selected protein structure model. Scripts available
through the AD4 development site (http://autodock/scripps.
edu/) were modified and used to automate the screening process.
Modifications to the scripts included exchanging the AD4
executable for the Vina executable and all subsequent necessary
changes for Vina functionality.
Structural Model Selection: Re-docking component
Five structures with co-crystallized rosiglitazone were down-
loaded from the Research Collaboratory for Structural Bioinfor-
matics (RCSB) Protein Data Bank (PDB) [38,39] (http://www.
pdb.org). The selected structure IDs were 1FM6 [40], 1ZGY [41],
2PRG [42], 3CS8 [43], and 3DZY [44]. These structures were
evaluated to identify a PPARc structural model that would be
appropriate for docking in a full agonist-like pose. Completeness of
structure, crystal resolution, and re-docking ability were the factors
considered. Re-docking refers to the ability of a docking program
to reproduce the co-crystallized binding geometry and orientation
of the associated ligand given a rigid macromolecule state. The
PDB structures were superimposed and rosiglitazone was isolated
from each protein structural model with the UCSF Chimera
software package [45].
Re-docking was conducted with both native and non-native
initial rosiglitazone conformations. Native refers to use of
coordinates for the co-crystallized ligand structure of the respective
protein structure model, whereas non-native refers to use of initial
coordinates not found in the original PDB file. For the native test,
each isolated rosiglitazone was re-docked into its respective protein
structure (e.g., five protein models each with a different
rosiglitazone coordinate files). For the non-native test, a single
rosiglitazone structure was randomly selected for re-docking into
all five structure models. Ligand flexibility and random initial
geometry for the ligand reduced possible bias associated with use
of a native ligand for one test structure, which was non-native for
the other four. A comparison of results for the native and non-
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conformation for rosiglitazone does not affect pose prediction as
the predicted poses for both test sets were similar (data not shown).
The non-native procedure involved docking of a single ligand
structure to the protein structures, which is similar to what would
be used for large-scale screening. Therefore, data from the non-
native re-docking was analyzed and provided here. Both the
superimposed positioning and the use of a single rosiglitazone
model established a relatively controlled test set: overlaid
coordinate space for the test structures, which translated to similar
grid areas, with a single ligand coordinate file for testing.
Structural Model Selection: Cross-docking component
Co-crystallized ligands from various PDB files were used for
cross-docking to test predictability for other known agonists.
Cross-docking refers to docking different ligand structures isolated
from multiple PDB structures of the same protein to a single
selected model structure. Ligands from 1FM9 [40], 2F4B [46],
2HWQ [47], 2I4J [48], 2I4P [48], 2VSR [49], 2VST [49], 3ET3
[50], 2VV0 [49], 2VV1 [49], 2ZK1 [51], and 2ZK2 [51] were
included in the library for this purpose (Table 3).
Small-scale in-house ligand library construction
Our small-scale ligand library included the rosiglitazone
structure from re-docking, several of the cross-docking ligands,
known PPARc agonists, and known inactive compounds.
Inclusion of the ligands from the re-docking and cross-docking
steps served as controls for successful and unsuccessful docking. A
search of published literature was conducted to find both naturally
and synthetically derived compounds shown experimentally to
either activate or not activate PPARc [52–55]. Structural models
for non-crystallized ligands were downloaded from the UCSF
ZINC database online (http://zinc.docking.org/). Any structures
not available through ZINC were built using the Dundee
PRODRG2 server [56] (http://davapc1.bioch.dundee.ac.uk/
prodrg/). Structures built with PRODRG2 were examined to
ensure conservation of stereochemistry. Charges for all of the
ligands in the database and the protein were generated using
ADT. Eighty-one compounds total were tested in this study. A
complete list of ligands included in the test library can be found in
Table S1.
Docking analysis for re-docking and cross-docking
The most energetically favorable pose for each ligand of the re-
docking (25 lowest energy poses) and cross-docking (108 lowest
energy poses) steps were used for analysis. Reference poses for root
mean-squared deviation (RMSD) calculations were taken from
crystal structure complexes for each ligand. These protein-ligand
complex structures were superimposed onto the test structures to
obtain a common coordinate space prior to the RMSD
calculation. For re-docking, RMSD values are exact given each
PPARc-rosiglitazone complex was used as the reference for the
respective results. However, the reported RMSD values for cross-
docking were relative rather than absolute given the co-crystallized
reference ligand coordinates are not relative to the protein
structure models used for testing. The idea of relative RMSD
stems from differences in side chain rotamers between the crystal
structures. Side chain position is governed, in part, by ligand
binding, which meant differences could be seen in binding cavity
residue positions when the rosiglitazone-bound test structures were
compared to each additional PPARc structure model. These
differences, which affect intramolecular interactions, resulted in
minor deviations of the backbone on some regions for the
superimposed structures relative to the test structure. This could
mean the position of each co-crystallized reference ligand relative
to the test structures was shifted slightly as well. However, there
were areas of the backbone that superimposed without noticeable
deviations. As the deviations between backbone positions were not
consistent, adjusting for any rotamer-induced shifts in co-
crystallized ligand coordinates was not feasible. Therefore, RMSD
values for docked poses for each ligand were deemed ‘‘relative’’ as
an acknowledgement of these minor variations in coordinates. An
average RMSD, population standard deviation, and variance were
calculated for each ligand (See Formulas S1). Re-docking and
cross-docking results for each ligand relative to each test protein
structure were deemed successful if the RMSD was less than 2.0 A ˚
[57].
Docking success versus failure for re-docking and cross-docking
was assessed qualitatively as well. Docked poses for rosiglitazone
on the surface of the protein or near the opening of the binding
cavity were deemed unsuccessful. Poses for which the molecule
was not properly oriented, such as the imidizole ring of
rosiglitazone positioned near the cavity opening rather than near
the rear of the pocket, were deemed unsuccessful as well given
such orientations would not match the co-crystallized coordinates.
Similar conditions relative to each cross-docking ligand were also
identified and assessed.
Docking analysis for small-scale VS
To prepare for analysis of the small-scale VS results,
interactions from various crystal structures were identified and
cataloged. Reported crystal structure interactions for the five
rosiglitazone-containing structures from the re-docking step and
six fatty acid-containing structures from the cross-docking step
were compiled using RCSB Ligand Explorer [58]. Residue atoms
common to more than one interaction list for a specific ligand type
were pooled and used as a reference list for analysis after docking.
As such, there were two master interaction lists: rosiglitazone-like
interactions (Table S2) and fatty acid-like interactions (Table S3).
Common interactions between the two lists were also noted (Table
S4).
Perl [59] scripts to automate pose distance measurement
calculations and pose interaction predictions were also composed
and used. The most energetically favorable docked pose for each
ligand relative to the macromolecule were pooled for analysis.
Only the potential for a ligand to fall into the full agonist category
of ligands was assessed in depth for this study. Full agonism has
been suggested to require interactions with Ser289, His323,
His449, and Tyr473, which are residues positioned in the portion
of the binding cavity proximal to the activation function-two (AF-
2) region (Figure S1). Interactions in this region govern AF-2
conformational changes necessary for PPARc activation. Distance
measurements between the top docked poses (77 lowest energy
poses) were calculated and used to predict interactions. Interac-
tions similar to those seen in the pooled crystal structure data were
deemed ‘‘successful’’. Potential hydrogen bonds were assessed
based on distances between the donor/acceptor heavy atoms of
the test ligand pose and four key residues. Lengths measuring less
than 3.3 A ˚ were considered potential hydrogen bond interactions
[52,58]. Potential hydrophobic interactions were set to a distance
threshold of 3.9 A ˚ between carbon atoms [58]. Predicted
interactions for each ligand were counted and a screen for the
presence of hydrogen bond interactions with the key residues listed
above was conducted to determine docking success.
Ligand Binding Assay
ESA was introduced at various concentrations (0.001–10 mM)
to solution containing PPARc protein complexed with a
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TM, Invitrogen). This
mixture was allowed to incubate for 20 hours. The ability of the
test compound, which here was ESA, to displace Fluormone
TM
was calculated as mean polarization, where a decrease in
polarization corresponded to an increase in ligand binding activity
as previously described [60].
Transfection of RAW 264.7 cells
RAW 264.7 mouse macrophage precursor cells (ATCC,
Manassas, VA) were grown in 24-well plates in DMEM high
glucose medium (Invitrogen, Carlsbad, CA) containing 10% fetal
bovine serum until 60–70% confluence. Transfected cells were
treated with varying concentrations of ESA (0, 1, 5, and 10 mM;
Sigma) or rosiglitazone (1 mM; Cayman Chemicals, Ann Arbor,
MI) for 24 hours. Other details of the protocol were as previously
described [60,61]. Relative luciferase activity was calculated as a
ratio between beginning and ending chemiluminescence values for
a 10-second time period.
Animal Procedures
The protocol for animal care and genotyping of the mice was
described previously [8]. An ESA-supplemented diet was tested
against a control (AIN-93G-based) diet in a dextran sodium sulfate
(DSS)-induced IBD mouse model. Sixty mice were divided
according to diet (ESA versus control), genotype (PPARc flfl;
MMTV-Cre-/PPARc-floxed versus epithelial cell- and immune
cell-specific PPARc flfl; MMTV-Cre+/PPARc-null), and DSS-
challenge. Ten mice (5 for each genotype) from the control diet
group and 9 mice (4 PPARc-floxed and 5 PPARc-null) from the
ESA diet group were not given DSS-treated water as a control for
the disease state. Drinking water with 2.5% DSS was administered
to the test mice for a period of seven days. Body weights and
disease activity index (DAI) values were recorded each day of the
seven-day DSS treatment period. Procedures for assigning DAI
values have been previously described [8]. Mice were euthanized
on day seven of the DSS challenge by CO2 asphyxiation followed
by secondary thoracotomy. Blood was withdrawn from the heart,
after which spleen, mesenteric lymph nodes (MLNs), and colonic
samples were examined for gross pathological lesions and isolated
from each mouse. Organs were examined to assign scores based
on size and macroscopic inflammatory lesions (0–3). Spleen and
MLN were crushed to produce single-cell suspensions for flow
cytometry, while colon samples were used for mRNA isolation and
histological examination. This study was approved by the Virginia
Tech Institutional Animal Care and Use Committee (IACUC) on
May 15, 2008 under animal welfare assurance number A3208-01.
Histopathology
Experimental design for histopathology was previously de-
scribed [8,20]. Epithelial erosion, mucosal thickness, and immune
cell infiltration were each assessed and scored (0–4) for colon cross-
sectional samples stained with hematoxylin and eosin from each
mouse.
Immunophenotyping
Whole blood and MLN cells were seeded onto 96-well plates
and treated with fluorochrome-conjugated antibodies. Monocyte/
macrophage subsets were assessed using anti-F4/80-PE-Cy5
(5 mg/mL, eBioscience) and anti-CD11b-Alexa Fluor 700
(2 mg/mL, eBioscience). The lymphocyte subset was assessed
with anti-CD4-Alexa Fluor 700 (2 mg/mL; BD Pharmingen),
anti-CD8-PerCp-Cy5.5 (2 mg/mL, eBioscience), anti-CD3 PE-
Cy5 (2 mg/mL; BD Pharmingen), anti-FoxP3-PE (2 mg/mL,
eBioscience), and anti-IL10-PE as previously described [62]. Flow
results were computed with a BD LSR II flow cytometer and data
analysis was performed with the FACS Diva software package
(BD).
Quantitative Real-Time RT-PCR
Total RNA was isolated from colonic tissue using procedures
previously described [20]. PCR was performed on complementary
DNA (cDNA) using Taq DNA polymerase (Invitrogen, Carlsbad,
CA) and previously described methods and conditions [8,20].
cDNA concentrations for genes of interest were examined by
quantitative real-time PCR using an iCycler IQ System and the iQ
SYBR green supermix (Bio-Rad). A standard curve was generated
for each gene using methods previously described [20]. In
addition, a melting curve analysis was performed for each product
using previously described methods [20] in order to determine the
number of products synthesized while excluding non-specific
products and primer dimers. Real-time PCR was used to quantify
the starting amount of nucleic acid of each unknown cDNA
sample. Primer sequences, the length of the PCR product, and
gene accession numbers have been outlined previously [20,61].
Primers used for this study were the forward and reverse cohorts of
VCAM-1, ICAM-1, IL-6, and b-actin [20].
Statistical analysis
Data were analyzed as a completely randomized design with
statistical significance assessed using the analysis of variance
(ANOVA) method. The general linear model procedure of the
Statistical Analysis Software (SAS) package (SAS Institute Inc.,
Cary, NC) was run for weight, DAI, flow cytometry data, and
histopathology scores to determine variance across and signifi-
cance between treatment groups. Statistical significance was
assessed based on a probability value (p) less than or equal to
0.05. Significant models were further assessed using the Fisher’s
Protected Least Significant Difference multiple comparison
method.
Results
Selection of structural model: Re-docking component
Structures with co-crystallized rosiglitazone (example given in
Figure S1) were used for re-docking because rosiglitazone was the
positive control in the experimental studies, it is a known PPARc
agonist, and the purpose of this docking feasibility test was to find
compounds that mimic rosiglitazone-induced activation. The top
scoring pose from each of the five 50-pose replicates was selected
for further analysis. This selection method was applied for each of
the five starting structures, giving a total of 25 poses for
comparison.
The RMSD and free energy of binding were averaged for the
five poses for each protein structure model (Table 1). Additionally,
the population-based standard deviation and variance were
calculated. The average pose RMSD values for three structures,
1FM6, 1ZGY, and 2PRG, were within 2.0 A ˚ of the crystal
structure position. Of these three, 1ZGY possessed the highest
standard deviation and variance values, which suggested that some
poses with low and high RMSD values should be present.
Examination of the poses for all five structures revealed that the
lowest RMSD value (0.99 A ˚) for all rosiglitazone poses was in the
1ZGY pose group as was the pose with the highest RMSD value
(3.05 A ˚). Thus, we favored the 1ZGY structure for further docking
studies because this structure enabled docking at the known
rosiglitazone binding position as well as docking at other
energetically favorable positions within the binding site, suggesting
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confirm this selection, cross-docking with known ligands from
other PDB structures was conducted.
Selection of structural model: Cross-docking component
1ZGY, 1FM6, and 2PRG were included in the cross-docking
testing as each showed successful re-docking and contained ligand-
binding domains without missing loops or sequence segments.
Structures 3CS8 and 3DZY were missing the H29-H3 loop and
did not result in accurate pose prediction for rosiglitazone.
Rosiglitazone poses for 3CS8 and 3DZY occupied the portion of
the binding cavity opening in which the H29-H3 loop would
normally sit (data not shown). This loop proved necessary for
successful agonist docking given the poor success rate of re-docking
in the absence of this region.
Vina was used for cross-docking instead of AD4 as the former
was more time-efficient for the number of ligands used and the
number of replicates to be carried out. It has also been reported
that Vina better predicts poses for ligands with higher numbers of
torsions [63], which was the case for some of the ligands used in
cross-docking. Replicates were conducted with Vina for two
reasons: to determine if replicates would be necessary in a larger-
scale study, and to aid in the protein structure model selection
process. Three replicate screens were run and each lowest-energy
pose was analyzed (3 protein models63 replicates612 li-
gands=108 lowest energy poses). Analysis of the cross-docking
results included a comparison of RMSD values, free energy of
binding, and number and identity of known interactions between
each ligand and PPARc based on the crystal structures of the
complexes. Results from comparison of RMSD values and free
energy of binding are listed in Table 2, with full ligand names
listed in Table 3. To simplify the process of cross-docking of
several ligands to multiple receptor structures, the initial crystal
protein-ligand complexes were superimposed prior to docking.
This practice allowed for RMSD values to be easily calculated
between the docked ligand poses and crystal reference poses as the
structures shared coordinate space.
The results relative to each of the test structure models were not
completely consistent across all the models. The lowest overall
average RMSD was seen with 1ZGY for the (2S)-ureidofibrate-like
derivative. This ligand did not dock as well into 1FM6 and 2PRG.
A similar comparative docking pattern was seen for 4-HDHA.
Only one ligand, PTG taken from PDB ID 2ZK1 (PTG-1), docked
within the 2.0 A ˚ threshold across the three structural models. It
should be noted here that the PTG structure taken from PDB ID
2ZK2 possessed different charges than the same compound from
2ZK1. The difference in charge is most likely due to the difference
in crystallization states. 2ZK2 had glutathione covalently bound to
PTG-1 as part of crystallization, whereas 2ZK1 did not. The
glutathione-PTG-1 compound would therefore have more atoms
over which charges would be distributed.
The RMSD, standard deviation, and variance values for
farglitazar, 9-HODE, indeglitazar, and PTG-1 showed the most
consistency across the three proteins, with PTG-1 showing
favorable average RMSD values and negligible variance for each
protein structure. For PTG-1, this suggested the ligand docked
similarly to all three protein structures. When the replicate poses
for the four compounds were assessed visually, the deviations for
the 9-HODE poses were due in large part to variation in the
placement of the hydrophobic tail portion, the PTG-1 poses
docked more similarly to 9-HODE than the PTG-1 reference
structure, and the indeglitazar poses occupied the middle portion
of the binding cavity rather than the rear activation site. The
placement of the indeglitazar and PTG-1 poses appeared to be
due to the shape of the binding cavity at the rear of the pocket,
which was mentioned previously to be the issue with farglitazar.
This hindrance was seen to a lesser degree with PTG-1 as there is
sufficient space to allow interactions despite lack of exact
congruence to the co-crystallized reference. Indeglitazar and
farglitazar poses were consistently unsuccessful due to the binding
cavity restriction, whereas PTG-1 occupied a fatty acid-like
orientation given the similarity of this compound to the types of
ligands that can appropriately fill the allotted molecular space.
All of the poses had negative calculated free energy of binding
values given the ligand structures and charge environment of the
binding cavity. These values were energetically feasible, but were
not an indication of the most favorable conformation for ligands
that did not agree with the reference structure geometry.
Therefore, RMSD and free energy of binding measurements
were not enough to determine successful cross-docking for PPARc.
A visual assessment of poses suggested rosiglitazone and fatty acid
compounds dock the best into the selected models. As such,
interactions from crystal structures containing these compounds
were used to generate a list of favorable interactions that might
indicate successful docking. The residues considered are listed in
Table S4.
Inclusion of the interaction criteria improved the target
structure model selection process. Based on the crystal structure
interactions common to rosiglitazone and known fatty acid
agonists, the number of possible interactions (Table S5) and
instances of key residue hydrogen bonding (Table S6) were
counted for all the poses. Both sets of data suggested that 1ZGY
was the most appropriate model relative to 1FM6 and 2PRG for
the purposes of this study. Poses docked into the 1ZGY model all
showed at least one key interaction, whereas the other two models
returned poses for some ligands that did not exhibit any known
interactions. Additionally, fatty acid and fatty acid-derivatives
returned the most favorable poses of all the cross-docking ligand
Table 1. Average RMSD and free energy of binding (kcal/mol) for re-docking of rosiglitazone (N=5).
RMSD kcal/mol
PDB ID Resolution (A ˚) Mean Standard Deviation Variance Mean Standard Deviation Variance
1FM6 2.1 1.76 0.561 0.314 27.58 0.487 0.237
1ZGY 1.8 1.91 0.925 0.856 27.19 0.247 0.061
2PRG 2.3 1.84 0.357 0.128 27.66 0.228 0.052
3CS8 2.3 2.81 0.101 0.010 26.63 0.184 0.034
3DZY 3.1 2.82 0.183 0.034 27.06 0.133 0.018
doi:10.1371/journal.pone.0024031.t001
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see 1ZGY as the predominate candidate for the target structure
model in a screen involving rosiglitazone-like and fatty acid
compounds.
Conjugated trienes showed association with PPARc in
silico
For the small-scale screen, a library of seventy-seven compounds
was selected. These compounds included known active and
inactive compounds, with alternate stereochemistry for some
structures. This test set allowed for screening of active versus
inactive, rosiglitazone-like versus non-TZDs, and molecularly
simple versus complex compounds. The interaction data (Tables
S7 and S8) reinforced the assumption that the selected target
structure model could accommodate rosiglitazone-like and fatty
acid compounds. The cross-docking ligands included in the screen
docked similarly to what was seen with the cross-docking test.
Most of the rosiglitazone-like compounds studied by Markt et al.
[55] showed successful docking. These compounds were Chemical
Abstracts Service (CAS)# 264908-13-6, CAS# 651724-09-3,
CAS# 853652-40-1, BRL48482, BVT13, CLX-M1, KRP297,
and NNC61-4424 (Table S1). Isomers of these compounds with
differences in stereochemistry were used as well. Some of these
structures did not dock as well, which was expected given it has
been suggested from crystal structure studies that chirality can
affect agonist activity [48]. We also saw lack of favorable docking
for bulkier compounds, which contain multiple ring and aromatic
components, and compounds with multiple hydroxyl groups.
These ligands included phenolic extracts taken from Glycyrrhiza
glabra roots isolated by Kuroda et al. [54], a-santonin-derived
compounds identified by Tanrikulu et al. [53], and flavonoids
screened by Salam et al. [52] (Table S1). The compounds from
Kuroda et al. [54] and Tanrikulu et al. [53] compounds were
numbered according to extraction fraction and deviation from the
original a-santonin scaffold, respectively. The Kuroda et al. subset
included compounds that induced low level activation. The
Tanrikulu et al. subset contained one highly active compound
(Tanrikulu_1), one moderately active compound (Tanrikulu_2),
and six inactive compounds (Tanrikulu_3 through Tanrikulu_8).
The selected Salam et al. compounds were apigenin, biochanin-A,
Table 2. Average RMSD and free energy of binding from cross-docking for various ligands relative to each listed PDB ID (top row)
(N=3).
1FM6 1ZGY 2PRG
RMSD (A ˚)
PDB Ligand ID Mean SD
1 Variance Mean SD Variance Mean SD Variance
243 2.82 0.199 0.040 2.82 0.014 0.000 2.60 0.040 0.002
570 3.19 0.000 0.000 3.08 0.007 0.000 3.13 0.050 0.003
4HD 1.81 0.365 0.134 1.40 0.018 0.000 2.19 0.236 0.056
9HO 1.73 0.184 0.034 1.85 0.270 0.073 1.70 0.162 0.026
DRH 2.74 0.030 0.001 1.55 0.209 0.044 2.17 0.251 0.063
DRJ 1.63 0.807 0.652 1.72 0.417 0.174 2.03 0.175 0.031
DRY 3.23 0.002 0.000 2.26 0.024 0.001 1.89 0.019 0.000
EHA 2.47 0.524 0.275 2.45 0.386 0.149 1.89 0.007 0.000
ET1 2.83 0.001 0.000 2.68 0.003 0.000 2.72 0.001 0.000
HXA 2.49 0.616 0.380 1.99 0.171 0.029 1.85 0.009 0.000
PTG-1 1.78 0.000 0.000 1.78 0.005 0.000 1.65 0.019 0.000
PTG-2 2.68 0.023 0.001 2.53 0.244 0.059 2.53 0.091 0.008
Free energy of binding (kcal/mol)
PDB Ligand ID Mean SD Variance Mean SD Variance Mean SD Variance
243 26.87 0.094 0.009 26.57 0.047 0.002 26.47 0.309 0.096
570 210.43 0.047 0.002 211.00 0.000 0.000 210.50 0.082 0.007
4HD 27.00 0.163 0.027 27.53 0.170 0.029 26.97 0.047 0.002
9HO 26.40 0.082 0.007 26.70 0.082 0.007 26.37 0.094 0.009
DRH 28.23 0.047 0.002 28.83 0.125 0.016 28.17 0.047 0.002
DRJ 28.63 0.094 0.009 28.80 0.294 0.087 28.37 0.094 0.009
DRY 210.03 0.047 0.002 210.13 0.047 0.002 210.37 0.047 0.002
EHA 210.10 0.082 0.007 210.10 0.082 0.007 210.60 0.000 0.000
ET1 28.10 0.000 0.000 28.50 0.000 0.000 28.50 0.000 0.000
HXA 27.00 0.327 0.107 27.90 0.082 0.007 27.33 0.047 0.002
PTG-1 27.00 0.000 0.000 27.23 0.047 0.002 27.20 0.082 0.007
PTG-2 27.17 0.170 0.029 27.10 0.082 0.007 27.47 0.094 0.009
1SD=Standard Deviation.
doi:10.1371/journal.pone.0024031.t002
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and vitexin. The unsuccessful docking of known active compounds
in these groups indicated the receptor structure was not
appropriate for docking of these molecule types.
All of the conjugated trienes docked successfully but with similar
geometry and energy scores, so a more detailed test for these
compounds was conducted to see if a predominant ligand could be
identified. AD4 was used to dock jacaric, catalpic, calendic,
eleostearic, and punicic acids into the selected structural model,
1ZGY. Three iterations of 50 poses each were run and the lowest
energy pose for each run for each fatty acid was selected and
compared (15 lowest energy poses). The numbers of potential
hydrogen bonds and hydrophobic interactions for each pose were
calculated (Table S8). The lowest energy pose with the most
potential hydrogen bond interactions was selected for each triene
and used for analysis. As there are no crystal structures available
with any of these compounds co-crystallized, interactions from
PDB structures with fatty acids bound were used to generate an
interaction reference list (Table S3). The four key residues that
formed hydrogen bonds with rosiglitazone also formed hydrogen
bonds with these fatty acids. Therefore, poses that possessed these
interactions were deemed successful agonists. Unsuccessful poses
were those lacking the agonist interactions and poses with the
reactive polar group pointed away from the activation site.
All the conjugated trienes showed favorable docked poses and
exhibited interactions with residues associated with PPARc
activation (Table 4). The triene poses occupied a space similar
to that seen with rosiglitazone (Figure 1), and exhibited
interactions with key residues. Of all the replicate poses for triene
docking, the ESA replicates consistently exhibited the most
negative free energy of binding (Table S9). Hydrogen bond
interactions with only two of the four key residues were seen;
however, it is not clear if interactions with all four residues are
absolutely necessary for activation, or if a reduced number of
interactions can still induce activation. It is feasible that a reduced
number of specific interactions may contribute to the specificity
seen with ligand-induced co-activator recruitment for PPARs. A
comparison of distance measurements for the interactions showed
two Y473-involved interactions for ESA, punicic acid, and jacaric
acid. Given the distance measurements, it was proposed that the
acid head group straddles Y473, with one oxygen atom closer to
one histidine side chain than the other. This was confirmed when
the poses were visually assessed. The number of hydrophobic
interactions was more consistent for the ESA poses compared to
punicic and jacaric acids. As previously mentioned, it is known
that punicic acid binds to PPARc and modulates its activity, while
ESA possesses greater antioxidant effects. Given the combination
of what was known experimentally about the compounds and the
predicted free energy of binding and interactions, ESA was
selected as a candidate for validation using a ligand-binding assay
and further experimental testing in vivo.
ESA bound to and modulated PPARc in vitro
The results of our molecular docking efforts and various
published studies [24,26–31,33,34] indicated that conjugated
trienes, specifically ESA, may bind to and modulate PPARc
activity. Ligand-binding and reporter activity assays were
conducted to test this assumption. A cell-free ligand-binding assay
was implemented to determine if ESA associated with PPARc in
vitro and possessed a similar depolarization pattern to rosiglitazone.
Table 3. Full names and structures for compounds listed by ligand ID in Table 2.
PDB Ligand ID PDB ID Reference Ligand Name
1
243 2VST [46] 13-hydroxyoctadecadienoic acid
(13-HODE)
570 1FM9 [37] GI262570
(Farglitazar)
4HD 2VV1 [46] (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic
acid
(4-HDHA)
9HO 2VSR [46] 9-hydroxyoctadecadienoic acid
(9-HODE)
DRH 2I4P [45] (2S)-2-[4-[2-(1,3-benzoxazol-2-yl-heptyl-amino)ethyl]phenoxy]-2-methyl-
butanoic acid
((2S)-ureidofibrate-like derivative)
DRJ 2I4J [45] (2R)-2-[4-[2-(1,3-benzoxazol-2-yl-heptyl-amino)ethyl]phenoxy]-2-methyl-
butanoic acid
((2R)-ureidofibrate-like derivative)
DRY 2HWQ [44] [(1-{3-[(6-benzoyl-1-propyl-2-naphthyl)oxy]propyl}-1H-indol-5-yl)oxy]acetic
acid
(5-substituted indoleoxyacetic acid analogue)
EHA 2F4B [43] (5-{3-[(6-benzoyl-1-propyl-2-naphthyl)oxy]propoxy}-1H-indol-1-yl)acetic
acid
(Indol-1-yl acetic acid)
ET1 3ET3 [47] 3-[5-methoxy-1-(4-methoxyphenyl)sulfonyl-indol-3-yl] propanoic acid
(indeglitazar)
HXA 2VV0 [46] Docosa-4,7,10,13,16,19-hexaenoic acid
PTG 2ZK1
2ZK2
[48] 15-deoxy-delta(12,14)-prostaglandin J2 (PTG)
Ligand IDs from respective PDB files were used. Ligand structures can be found in Table S1.
1Abbreviations for ligands mentioned in the text are in parentheses following the full name of the compound.
doi:10.1371/journal.pone.0024031.t003
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similar to that seen with the rosiglitazone positive control with no
significant difference between the two curves (Figure 2A).
An assessment of PPARc activity modulation was conducted
using RAW 264.7 cells and varying ESA concentrations (0–
10 mM). Relative luciferase activity was measured to determine
ligand-induced activation. The reporter assay suggested ESA does
modulate PPARc activity, but at a concentration 10-fold higher
than the rosiglitazone control (Figure 2B), suggesting that there
may be a difference in either potency or uptake by the cells
between both compounds.
ESA ameliorated clinical signs of IBD
Under our DSS-induced IBD model, ESA significantly
ameliorated IBD in mice with the wild phenotype (i.e., PPARc-
floxed). This observation was based on the significant difference
between DAI for the last four days of the seven-day challenge
(Figure 3). IBD-related disease phenotypes were milder in the
ESA-fed PPARc-expressing group of mice compared to the ESA-
fed cell-specific PPARc-null mice. The control groups (no ESA) for
both genotypes showed no improvement in IBD phenotypes over
the seven-day time course. Therefore, ESA was effective in
ameliorating disease-associated phenotypes in mice with DSS
colitis through a PPARc-dependent mechanism.
Immunophenotypes for harvested tissues
Changes in immune cell subsets due to DSS-induced colitis
were assessed in the harvested tissues to investigate the modulation
of inflammation by ESA (Figure 4). Flow cytometry was used to
characterize the phenotype of macrophages and T cell subsets.
DSS augmented the percentages of monocytes or macrophages in
the blood and spleen (Figure 4A and 4C). A significant increase in
blood monocytes was found in ESA-treated mice. The PPARc-
expressing mice on the ESA diet exhibited a higher percentage of
monocytes expressing lymphocyte antigen 6 complex-high
(Ly6C
hi), which was not seen in the PPARc-null group
(Figure 4B) indicating a PPARc dependency of this effect. Higher
levels of IL-10 were observed in the spleen of the ESA-fed mice for
both genotypes although these numerical differences were not
statistically significant between the two diets for the PPARc-
expressing genotype (Figure 4D). Lastly, we found a numerical
decrease in CD8
+ T-cells in the ESA diet group (Figure 4E), where
the change was PPARc-independent.
Histological trends mimicked clinical activity
There was a significant decrease in epithelial erosion (Figure 5A),
mucosal thickness (Figure 5B), and immune cell infiltration
(Figure 5C) in the ESA-fed PPARc-expressing mice but not in
ESA-fed PPARc-null mice. This suggested amelioration of
experimental IBD phenotypes by ESA is PPARc-dependent. This
agreed with the DAI data and further indicated an ESA-associated
PPARc-dependent improvement in IBD phenotypes.
Gene expression suggested PPARc-dependent and
-independent mechanisms
There was a marked decrease in IL-6 and VCAM-1 mRNA
expression between the control- and ESA-fed PPARc-expressing
groups (Figure 6A and 6B). The IL-6 decrease appeared to be
PPARc-independent, while the VCAM-1 decrease was PPARc-
dependent. We also found a decrease in ICAM-1 expression
between the control and ESA diet groups, but this decrease also
occurred in the PPARc-null mice suggesting ESA can induce
ICAM-1 regulation in a PPARc-independent manner (Figure 6C).
Discussion
The VS model protein structure and parameters used in this
study allowed for prediction of docking conformations for
Figure 1. Predicted docked conformations for a-eleostearic
(purple), punicic (cyan), calendic (orange), jacaric (green), and
catalpic (gold) acids relative to the rosiglitazone-occupied
portion of the binding cavity (mesh surface) in the rigid PPARc
structure model. Key residues with which hydrogen bonding occurs
are labeled. Atom-specific coloring: red=oxygen; gray=carbon; blue=
nitrogen. Table 4 contains distance measurements for each docked
pose.
doi:10.1371/journal.pone.0024031.g001
Table 4. Distance measurements (in Angstroms [A ˚]) for
docked conjugated triene poses displayed in Figure 1.
Ligand Color Residue Distance (A ˚) kcal/mol
eleostearic acid purple H323.NE2 3.16 25.6
Y473.OH 3.01
Y473.OH 3.27
punicic acid cyan H449.NE2 2.84 24.28
Y473.OH 3.03
Y473.OH 3.07
calendic acid orange H449.NE2 2.81 24.47
Y473.OH 3.10
catalpic acid gold S289.OG 3.05 24.48
H323.NE2 3.03
Y473.OH 3.26
jacaric acid green H449.NE2 2.84 24.5
Y473.OH 3.16
Y473.OH 3.10
rosiglitazone gray mesh S289.OG 3.02 N/A
H323.NE2 2.83
H449.NE2 3.02
Y473.OH 2.85
Distances were measured between carboxylic oxygen atoms of fatty acids and
listed atoms for each residue. Free energy of binding is measured in kilocalories
per mole of ligand (kcal/mol). No value is listed for rosiglitazone as this refers to
the crystal conformation (denoted ‘‘N/A’’) Residues are labeled as the amino
acid designation plus the atom name (e.g., S289.OG refers to the oxygen atom
in the gamma position on serine 289).
doi:10.1371/journal.pone.0024031.t004
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results for rosiglitazone, cross-docking results for PTG-1 and 9-
HODE, and the conjugated triene docking all suggested 1ZGY is
appropriate for screening fatty acids and TZD-like compounds.
Potential for docking of fatty acid derivative partial agonists, like
(2S)-ureidofibrate-like derivative, was also seen, but not fully
assessed for this study as full agonism was the binding type of
interest. Thus, we have successfully established a VS parameter set
appropriate for a large-scale PPARc full agonist search amongst
fatty acids and fatty acid derivatives.
Information regarding interactions known to occur with PPARc
agonists is a suitable means to identify docking success. However,
the success rate may be improved by incorporating even more
criteria. Such criteria include a more extensive list of key
interactions and/or establishment of distinct lists to specify
interactions characteristic of each ligand category (e.g., full
agonist, partial agonist, and antagonist). Based on the number of
interactions and presence of interactions with key residues, we
were able to determine which ligand types do and do not fit our
selected target structure model. Combining this with RMSD data
allowed us to see which types of ligands dock away from the
binding cavity given the molecular environment of the selected
target structure model. This information regarding ligands that
would be excluded in a screen for compounds that interact
similarly to what is seen with rosiglitazone can be used to identify
one or more additional target structure models to incorporate into
a large-scale screen. RMSD data, however, would not be available
from a screen of unknowns, and conclusions would therefore have
to be drawn from the interaction and free energy data.
Due to the high degree of precision observed with the cross-
docking ligands, it was determined that a single pose for each
ligand would be sufficient for the initial analysis step in a large-
scale screen. Replicates were necessary for the pre-screening
analysis in which parameters and structure models were tested for
predictability. Replicates are useful in docking studies to ensure
any conclusions are based on consistent interactions. However,
running replicates for a library numbering in the thousands is
computationally time-consuming and less than practical given
replicate poses may possess geometry that is exactly or close to the
same. Rather than run replicates on the entire library of
compounds, it would be feasible to run more detailed docking
with compounds selected as successful binders of interest with the
potential for experimental verification.
We observed a complementary relationship between the
experimental ESA-IBD study and the computational screening
results. In a recent review, we mentioned previous studies in which
dual- or pan-agonistic effects have been associated with conjugated
trienes [64]. This information, coupled with other published
studies regarding synthetic agonists and inactive compounds,
provided a means to develop and test computational methods for
identifying natural agonists. Our docking analysis suggested ESA
possessed a more favorable binding energy compared to the other
conjugated trienes. Though comparative relationships have not
been established between ESA and all the tested trienes, we do
Figure 2. Ligand-binding (A) and reporter assay (B) results for ESA bound to PPARc with rosiglitazone (Ros) as a positive control. (A)
Ligand binding was assessed as a measure of mean polarization for the displaced Fluormone
TM molecule versus increasing concentrations of either
ligand. (B) Reporter activity was measured as relative luciferase activity for various concentrations of ESA versus 1 mM Ros. Error bars represent
standard deviation, while asterisks (*) indicate significance (p#0.05) between the data sets.
doi:10.1371/journal.pone.0024031.g002
Figure 3. Effect of ESA on disease activity scores for PPARc-expressing (A) and PPARc-null (B) mice with experimental IBD. PPARc-
null refers to lack of functional PPARc product in colon epithelial and immune cells only. Data points represent averaged disease scores for each
group with error bars representing standard deviation. Asterisk (*) indicates significance (p#0.05).
doi:10.1371/journal.pone.0024031.g003
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acid in mice [65]. It is plausible that the differences in efficacy
between the compounds is interaction-related, which may result in
conformational changes that attenuate co-activator recruitment
and subsequent transcriptional regulation. The interaction aspect
may have been picked up by our study, but the dynamic
significance was not. This second aspect would require further
computational testing to see if differences in protein stability and
conformation can be detected between the protein-ligand
complexes.
The ligand binding and reporter assays verified that ESA binds
to and modulates PPARc. Our docking study suggested fewer
interactions occurred in the PPARc-ESA complex compared to
PPARc-rosiglitazone. It is possible that the absence of interactions
with S289 and H449 could result in a different level of ligand-
induced activity attenuation or the interactions with H323 and
Y473 may be more important for fatty acid-induced agonism.
Given the different levels of agonism, which is ligand-dependent, it
is plausible that the specificity toward anti-inflammatory mecha-
nisms observed as PPARc-dependent in the pre-clinical trial were
influenced by some difference in agonism specific to ESA. This
notion is further supported by the absence of rosiglitazone-
associated phenotypes seen in studies published by other groups
[65,66]. Both the Shah et al. and Ramakers et al. studies involved
testing rosiglitazone against DSS-induced colitis in mice [65,66].
Ramakers et al. showed weight gain in mice treated with
rosiglitazone prior to DSS challenge, followed by significantly
greater weight loss compared to the control after DSS challenge
[66]. Increases in the severity of colitis-specific colon phenotypes
were also seen, but with a decrease in inflammation [66]. The
Figure 4. Effect of ESA on immune cell subsets of PPARc-expression and PPARc-null mice with experimental IBD. Tissues examined
included blood (A and D) and spleen (B, C, and E). Values represent least square means for percentage of gated cells with error bars to indicate
standard error. Letters indicate significance (p#0.05) where a shared letter indicates groups which are not statistically significantly different.
doi:10.1371/journal.pone.0024031.g004
Figure 5. Effect of ESA on histopathological lesions in colons from PPARc-expressing and PPARc-null mice with experimental IBD.
Epithelial erosion (Erosion) (A), immune cell infiltration (Infiltration) (B), and mucosal thickness (Thickness) (C) were assessed and averaged for all the
DSS-treated group of samples. Data are presented as mean score with error bars to indicate standard deviation. Letters indicate significance (p#0.05)
where a shared letter indicates groups which are not statistically significantly different.
doi:10.1371/journal.pone.0024031.g005
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induced decrease in macrophage recruitment, but showed no
other significant changes to the levels of other cytokines [65].
We have shown that the immune modulatory actions of ESA
may be both PPARc-dependent and PPARc-independent in mice
with experimental IBD, although its effects on disease activity and
colonic lesions are dependent on expression of PPARc by immune
and epithelial cells. It is known that PPARc is highly expressed in
immune cells, intestinal epithelial cells (IECs), and adipocytes, with
lower expression levels throughout various tissues of the body.
Recently, our group published work in which the severity of IBD
was tested in a mouse model for IEC-specific PPARc deletion in a
C57BL/6 background [67]. It was determined that the absence of
PPARc from IECs resulted in significantly worse disease scores,
greater loss of body weight, and increased inflammation in the
colon, spleen, and MLN compared to mice expressing PPARc
[67]. Further, it was concluded that the presence of PPARc in IEC
contributes to anti-inflammatory effects, regulation of immune cell
distribution, and gene expression regulation necessary to counter-
act IBD symptoms [67].
Additionally, there are studies in which PPARc expression and
the effect of ESA on disease pathogenesis have been evaluated in
breast cancer cell lines [27,68], pre-adipocytes [69], and colon
cancer cell lines [70]. In all cases the fatty acid was capable of
significantly ameliorating the disease via PPARc-dependent
responses such as induced apoptosis of cancer cells [27,68,70]
and reduced lipid storage during differentiation [69]. Other
conjugated trienes, such as punicic acid and catalpic acid [23,24]
have shown reduced inflammation responses in cancer, cardio-
vascular disease [71], and obesity [23,24,71]. All of these studies
are strong examples of how PPARc mediates inflammatory,
metabolic, proliferation, signal transduction, and cellular motility
processes [67] in various cell types.
It is possible that the presence of other nuclear receptors in the
cells play a role in ESA-mediated effects. PPARd in the colon may
play a role in ESA-mediated IBD amelioration given the possibility
of dual-agonist and pan-agonist modulation seen with PPARs, and
the ability of all three PPARs to accommodate fatty acids. Further
computational and experimental tests would be necessary to
determine whether ESA mediates both PPARc and PPARd
transcriptional regulation, which has been previously described for
CLA [72]. The anti-inflammatory responses induced by ESA,
which appeared to be PPARc-independent, might also be
attributed to other unforeseen targets in the system. For instance,
we previously described the potential of PPARc agonists to bind to
lanthionine synthetase component C-like protein 2 (LANCL2)
[60]. Such an association is one proposed molecular mechanism of
regulating disease-related inflammatory effects in a PPARc-
independent manner.
Beyond what is seen in IBD, it has been shown that ESA binds
to and activates estrogen receptors in breast cancer cell lines [73].
It is also known that hepatocyte nuclear factor-4a (HNF4a), which
is essential for maintaining lipid homeostasis via gene regulation
and regulating hepatocyte differentiation, is activated by fatty acids
[74]. It has been suggested that PPARa ligands can interfere with
HNF4a activity [75], but the mechanism by which this occurs is
not fully understood. As conjugated trienes like punicic acid
activate PPARa in adipocytes [24], and PPARa and fatty acids are
present in liver tissue also, it seems feasible that conjugated trienes
could come in contact with and bind HNF4a as well. To our
knowledge such a study involving HNF4a and ESA or any other
conjugated trienes has not been conducted.
The ability of the binding cavity to accommodate many
different ligand types represents a major technical obstacle when
performing computational docking into PPARc as a therapeutic
target. The issue stems from the dynamic nature of the binding
cavity and changes in protein conformation necessary to
accommodate different agonists. This dynamic nature is not
possible with rigid macromolecule docking techniques, and
incorporation of flexibility can be difficult given the number of
residues that can possess variable positions and the number of
possible rotamers for each residue. The rigidity of crystal
structures combined with the variability of residue side chain
positions proved an issue for docking non-native ligands to the
selected structure model. For example, the docked poses for
farglitazar across the three protein structure models examined in
the cross-docking step reflected a lack of appropriate molecular
volume at the rear of the binding pocket to accommodate the
benzyl ketone group on the ligand (Figure 7A). When the three
structure models were compared to the 1FM9 crystal structure in
which farglitazar was co-crystallized, the space necessary to
accommodate the benzyl ketone group of farglitazar was missing
given the differences in the side chain positions for Phe282 and
Phe363 (Figure 7B). These residues do not pose an issue for
rosiglitazone docking, but occupied the portion of the cavity in
which farglitazar should have docked, which prevented successful
cross-docking of this compound to the selected structure models.
As such, selection of a single model to appropriately accommodate
Figure 6. Effect of ESA on colonic concentrations of IL-6 (A), VCAM-1 (B), and ICAM-1 (C) in PPARc-expressing and PPARc-null mice
with experimental IBD. The mean ratio of expression for each protein relative to constitutively expressed b-actin is shown with error bars to
indicate standard deviation. Letters indicate significance (p#0.05) where a shared letter indicates groups which are not statistically significantly
different.
doi:10.1371/journal.pone.0024031.g006
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with a diverse ligand library are two avenues toward identifying
PPARc agonists in silico. The first technique is used widely, but the
second is not as common due to the amount of time necessary to
properly identify target structure models. Given the molecular
exclusion of the more hydrophobic compounds in our small-scale
screen, the second technique would be ideal for dealing with a
diverse library, such as the one we have constructed. Therefore,
further testing with additional protein structure models capable of
accommodating bulkier and more hydrophobic compounds would
be necessary.
An additional technique for improving predictability is
molecular dynamics simulation and analysis, which is also
extremely time consuming and can prove problematic since
parameters for ligands must be developed. Conformational
sampling of the PPARc binding cavity via MD is one means of
gleaning useful information in a relatively short amount of time.
This technique would provide information about predominant
conformations adopted by PPARc that would aid in the selection
of multiple target structure models for docking, and can be easily
verified by the large number of available crystal structures.
PPARc has proven a difficult protein to explore as a drug target
given dynamic and specificity issues. The large binding cavity and
ability of the protein to accommodate a wide range of compounds
presents an issue for rigid docking screening. The ability of the
protein to bind compounds of different compound families
requires a degree of ligand diversity that is often not employed
in conventional VS studies. As a means to improve our method,
we are currently testing additional PPARc crystal structures as
docking targets. As a consequence of this study, we have
established a need for at least one additional target structure
model that can accommodate bulker compounds. An analysis of
MD simulations for unbound active, bound active, and unbound
inactive forms of PPARc are ongoing. These simulations,
combined with further analysis of available crystal structure
models, will allow us to develop additional target structure models.
Incorporating conformational variability by screening against
multiple protein conformations of the same protein should
improve our screening process. We propose matching ligand and
protein pharmacophores prior to screening to reduce the
incidence of screening ligands against a protein structure into
which the ligands cannot fit or where the charge environment is
inappropriate.
The diversity of our compound database is being expanded as
well, and will include an extensive list of known PPARc agonists,
decoy compounds that mimic known agonist structure but are
inactive toward PPARc, drugs currently available for treatment of
other diseases, and extracts tested experimentally for PPARc
modulation. Such a library would improve enrichment, which is
part of the separation of binders from non-binders. Further,
inclusion of a weighting system based on the occurrence of known
interactions would improve the separation process. With a diverse
library in which available therapeutics are included, it may be
possible to identify lesser known drug interactions with PPARc
linked to side effects seen with patients taking medications for
cancer and neurological diseases. Given the success of our current
study and the pending improvements to our method for testing of
diverse ligand types, we are making progress toward an extensive
and highly effective means to computationally identify feasible
PPARc-targeted drug candidates. Ideally, the established methods
could be applied to the other PPARs, other nuclear hormone
receptors, and alternate protein family targets where similar
considerations must be made.
This study exemplifies how experimental methods can be used
to complement and verify computational predictions. We have
demonstrated that it is possible to predict ligand association given
information known about the binding cavity of the target. We have
also established a means to reduce the need for researcher
intervention in assessing successful binding by incorporating a
search for key interactions. More specifically, we have successfully
established a protocol for screening fatty acid compounds against
PPARc for agonism, and were able to predict that ESA and other
conjugated trienes would bind to and activate PPARc using
molecular docking. These predictions have been verified through
in vitro assays both here and in our previous work [24,34]. In vivo
efficacy was assessed as well to determine if disease-associated
benefits could be seen given the activation of PPARc by ESA. In
this regard, ESA did induce both PPARc-dependent and
-independent responses that ameliorated disease activity and
intestinal lesions in IBD. The scope of this work implies the
techniques described here can aid in streamlining drug discovery
and development techniques as the technology develops.
Figure 7. Visual assessments of molecular surface differences that result in unsuccessful docking of specific ligand types to the
selected PPARc structure model. Farglitazar is represented in both panels with atom-specific coloring. (A) 1ZGY and 1FM9 surface
representations are green mesh and solid gray, respectively. The three poses predicted for farglitazar relative to 1ZGY are shown in magenta, cyan,
and yellow. (B) Side chain rotamers for F282 and F363 are responsible for the differences in cavity surface at the rear of the cavity. Surface colors for
1ZGY and 1FM9 are the same as in (A). Atom-specific coloring: gray/black=carbon, blue=nitrogen, red=oxygen, white=hydrogen, and
yellow=sulfur.
doi:10.1371/journal.pone.0024031.g007
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Figure S1 Colored ribbon representation of PPARc showing
three layers of helical ‘‘sandwich’’, and co-crystallized rosiglitazone
(PDB ID 1FM6 [40]). Helices for each layer are colored, with helix
H12, which sits at the rear of the binding cavity (AF-2 region),
colored in red. Rosiglitazone is colored in green, with oxygen,
nitrogen, and sulfur atoms colored red, blue, and yellow,
respectively. The insert (upper right) shows a close-up view of the
molecular surface of the binding cavity. The thiazolidinedione head
group of rosiglitazone sits at the rear of the binding cavity where it
can interact with S289, H323, H449, and Y473 in order to change
the conformation of the AF-2 region and activate the protein.
(TIF)
Table S1 List of ligands used for virtual screening.
(DOC)
Table S2 List of atoms for key residues common to selected
rosiglitazone crystal structures used to assess potential interactions
between docked poses and the protein structure model.
(DOC)
Table S3 List of atoms for key residues common to selected fatty
acid-bound crystal structures used to assess potential interactions
between docked poses and the protein structure model.
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Table S4 List of atoms for key residues common to rosiglita-
zone- and fatty acid-containing PDB structures used to assess
potential interactions between docked poses and the protein
structure model.
(DOC)
Table S5 Predicted hydrophobic and hydrogen bond interac-
tions for ligands in cross-docking test set relative to a reference list
of interactions common to rosiglitazone and selected fatty acids.
Poses were taken from docking of each ligand into each of the
three listed PPARc PDB files (top row). Ligand IDs refer to
compounds listed in Table 3.
(DOC)
Table S6 Presence or absence of potential hydrogen bond
interactions between indicated residues of selected protein
structure models and replicate poses of ligands listed by ID. A
single ‘‘x’’ indicates one potential interaction for the listed residue
was found for the specified ligand, whereas more than one ‘‘x’’
indicates more than one interaction (e.g., ‘‘xx’’ indicates two
interactions found). (N=3)
(DOC)
Table S7 Predicted hydrophobic and hydrogen bond interac-
tions for ligands in small-scale screening test set relative to a
reference list of interactions common to rosiglitazone and selected
fatty acids (Table S4). Poses were taken from docking of each
ligand into each of the three listed PPARc PDB files (top row).
Predicted free energy of binding is listed as kcal/mol.
(DOC)
Table S8 Presence or absence of potential hydrogen bond
interactions between indicated residues of selected protein
structure models (top row) and ligand poses. A single ‘‘x’’ indicates
one potential interaction for the listed residue was found for the
specified ligand, whereas more than one ‘‘x’’ indicates more than
one interaction (e.g., ‘‘xx’’ indicates two interactions found).
(DOC)
Table S9 Predicted free energy of binding and interaction
counts for conjugated trienes. Docking was performed using AD4
with three top-binding replicates for each ligand (150 total
conformations). The highest energy conformation with the highest
number of hydrogen bonds was used for analysis in Table 4.
(DOC)
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